you attend your first study visit on week 0. staff measure your weight and height, collect basic health information, and give you counseling about diet and physical activity. you are randomly assigned to receive either cagrilintide or placebo. both are clear solutions for injection that are given under the skin (subcutaneous injection). the exact amount of medication is set by the study protocol.

you receive a subcutaneous injection of the assigned product at regular intervals as explained by the study team. injections continue for 26 weeks. each injection is given in the abdomen or thigh according to the instructions. you keep following the diet and physical activity counseling throughout this period.

you return to the clinic at scheduled times (often weekly or every few weeks) for weight measurement, safety checks, and to receive your next injection. any side effects are recorded, and counseling is reinforced.

at week 26 you have a final weight measurement, complete the last injection if applicable, and receive a final counseling session. study medication stops after this visit.

after stopping the medication you attend follow‑up visits until week 33 to monitor for any adverse events. no further study medication is given.

at week 33 you have a final safety assessment, answer any remaining questionnaires, and the study is considered complete for you.